An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas is a PHASE1 clinical asset sponsored by Affiliated Hospital of Nantong University in Relapsed/Refractory B-cell Lymphoma. SEO and diligence focus: RN1701 injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Relapsed/Refractory B-cell Lymphoma
Modality: cell therapy
Target: RN1701 injection
Sponsor: Affiliated Hospital of Nantong University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: RN1701 injection
View original source fields
Condition raw: Relapsed/Refractory B-cell Lymphoma
Condition normalized: Relapsed/Refractory B-cell Lymphoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: RN1701 injection
Target normalized: RN1701 injection